Literature DB >> 28745630

Subpial Adeno-associated Virus 9 (AAV9) Vector Delivery in Adult Mice.

Takahiro Tadokoro1, Atsushi Miyanohara1, Michael Navarro1, Kota Kamizato1, Stefan Juhas2, Jana Juhasova2, Silvia Marsala1, Oleksandr Platoshyn1, Erik Curtis3, Brandon Gabel3, Joseph Ciacci3, Nada Lukacova4, Katarina Bimbova4, Martin Marsala5.   

Abstract

The successful development of a subpial adeno-associated virus 9 (AAV9) vector delivery technique in adult rats and pigs has been reported on previously. Using subpially-placed polyethylene catheters (PE-10 or PE-5) for AAV9 delivery, potent transgene expression through the spinal parenchyma (white and gray matter) in subpially-injected spinal segments has been demonstrated. Because of the wide range of transgenic mouse models of neurodegenerative diseases, there is a strong desire for the development of a potent central nervous system (CNS)-targeted vector delivery technique in adult mice. Accordingly, the present study describes the development of a spinal subpial vector delivery device and technique to permit safe and effective spinal AAV9 delivery in adult C57BL/6J mice. In spinally immobilized and anesthetized mice, the pia mater (cervical 1 and lumbar 1-2 spinal segmental level) was incised with a sharp 34 G needle using an XYZ manipulator. A second XYZ manipulator was then used to advance a blunt 36G needle into the lumbar and/or cervical subpial space. The AAV9 vector (3-5 µL; 1.2 x 1013 genome copies (gc)) encoding green fluorescent protein (GFP) was then injected subpially. After injections, neurological function (motor and sensory) was assessed periodically, and animals were perfusion-fixed 14 days after AAV9 delivery with 4% paraformaldehyde. Analysis of horizontal or transverse spinal cord sections showed transgene expression throughout the entire spinal cord, in both gray and white matter. In addition, intense retrogradely-mediated GFP expression was seen in the descending motor axons and neurons in the motor cortex, nucleus ruber, and formatio reticularis. No neurological dysfunction was noted in any animals. These data show that the subpial vector delivery technique can successfully be used in adult mice, without causing procedure-related spinal cord injury, and is associated with highly potent transgene expression throughout the spinal neuraxis.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28745630      PMCID: PMC5612300          DOI: 10.3791/55770

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  10 in total

1.  Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons.

Authors:  Sandra Duque; Béatrice Joussemet; Christel Riviere; Thibaut Marais; Laurence Dubreil; Anne-Marie Douar; John Fyfe; Philippe Moullier; Marie-Anne Colle; Martine Barkats
Journal:  Mol Ther       Date:  2009-04-14       Impact factor: 11.454

2.  Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates.

Authors:  Steven J Gray; Valerie Matagne; Lavanya Bachaboina; Swati Yadav; Sergio R Ojeda; R Jude Samulski
Journal:  Mol Ther       Date:  2011-04-12       Impact factor: 11.454

3.  Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus.

Authors:  X Xiao; J Li; R J Samulski
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

4.  Motor neuron transduction after intracisternal delivery of AAV9 in a cynomolgus macaque.

Authors:  Peter Bell; Christian Hinderer; Jean-Pierre Louboutin; Hongwei Yu; Rebecca Grant; Erin Bote; James M Wilson
Journal:  Hum Gene Ther Methods       Date:  2015-04       Impact factor: 2.396

5.  Translational fidelity of intrathecal delivery of self-complementary AAV9-survival motor neuron 1 for spinal muscular atrophy.

Authors:  Marco A Passini; Jie Bu; Amy M Richards; Christopher M Treleaven; Jennifer A Sullivan; Catherine R O'Riordan; Abraham Scaria; Adrian P Kells; Lluis Samaranch; Waldy San Sebastian; Thais Federici; Massimo S Fiandaca; Nicholas M Boulis; Krystof S Bankiewicz; Lamya S Shihabuddin; Seng H Cheng
Journal:  Hum Gene Ther       Date:  2014-04-28       Impact factor: 5.695

6.  Therapeutic AAV9-mediated suppression of mutant SOD1 slows disease progression and extends survival in models of inherited ALS.

Authors:  Kevin D Foust; Desirée L Salazar; Shibi Likhite; Laura Ferraiuolo; Dara Ditsworth; Hristelina Ilieva; Kathrin Meyer; Leah Schmelzer; Lyndsey Braun; Don W Cleveland; Brian K Kaspar
Journal:  Mol Ther       Date:  2013-09-06       Impact factor: 11.454

7.  Improving single injection CSF delivery of AAV9-mediated gene therapy for SMA: a dose-response study in mice and nonhuman primates.

Authors:  Kathrin Meyer; Laura Ferraiuolo; Leah Schmelzer; Lyndsey Braun; Vicki McGovern; Shibi Likhite; Olivia Michels; Alessandra Govoni; Julie Fitzgerald; Pablo Morales; Kevin D Foust; Jerry R Mendell; Arthur H M Burghes; Brian K Kaspar
Journal:  Mol Ther       Date:  2014-10-31       Impact factor: 11.454

8.  Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes.

Authors:  Kevin D Foust; Emily Nurre; Chrystal L Montgomery; Anna Hernandez; Curtis M Chan; Brian K Kaspar
Journal:  Nat Biotechnol       Date:  2008-12-21       Impact factor: 54.908

9.  In vivo gene knockdown in rat dorsal root ganglia mediated by self-complementary adeno-associated virus serotype 5 following intrathecal delivery.

Authors:  Qinghao Xu; Beverly Chou; Bethany Fitzsimmons; Atsushi Miyanohara; Veronica Shubayev; Camila Santucci; Michael Hefferan; Martin Marsala; Xiao-Ying Hua
Journal:  PLoS One       Date:  2012-03-05       Impact factor: 3.240

10.  Potent spinal parenchymal AAV9-mediated gene delivery by subpial injection in adult rats and pigs.

Authors:  Atsushi Miyanohara; Kota Kamizato; Stefan Juhas; Jana Juhasova; Michael Navarro; Silvia Marsala; Nada Lukacova; Marian Hruska-Plochan; Erik Curtis; Brandon Gabel; Joseph Ciacci; Eric T Ahrens; Brian K Kaspar; Don Cleveland; Martin Marsala
Journal:  Mol Ther Methods Clin Dev       Date:  2016-07-13       Impact factor: 6.698

  10 in total
  4 in total

1.  Precision spinal gene delivery-induced functional switch in nociceptive neurons reverses neuropathic pain.

Authors:  Takahiro Tadokoro; Mariana Bravo-Hernandez; Kirill Agashkov; Yoshiomi Kobayashi; Oleksandr Platoshyn; Michael Navarro; Silvia Marsala; Atsushi Miyanohara; Tetsuya Yoshizumi; Michiko Shigyo; Volodymyr Krotov; Stefan Juhas; Jana Juhasova; Duong Nguyen; Helena Kupcova Skalnikova; Jan Motlik; Hana Studenovska; Vladimir Proks; Rajiv Reddy; Shawn P Driscoll; Thomas D Glenn; Taratorn Kemthong; Suchinda Malaivijitnond; Zoltan Tomori; Ivo Vanicky; Manabu Kakinohana; Samuel L Pfaff; Joseph Ciacci; Pavel Belan; Martin Marsala
Journal:  Mol Ther       Date:  2022-05-05       Impact factor: 12.910

2.  Spinal parenchymal occupation by neural stem cells after subpial delivery in adult immunodeficient rats.

Authors:  Martin Marsala; Kota Kamizato; Takahiro Tadokoro; Michael Navarro; Stefan Juhas; Jana Juhasova; Silvia Marsala; Hana Studenovska; Vladimir Proks; Tom Hazel; Karl Johe; Manabu Kakinohana; Shawn Driscoll; Thomas Glenn; Samuel Pfaff; Joseph Ciacci
Journal:  Stem Cells Transl Med       Date:  2019-12-04       Impact factor: 6.940

3.  A long-range, recurrent neuronal network linking the emotion regions with the somatic motor cortex.

Authors:  Yihan Wang; Qian-Quan Sun
Journal:  Cell Rep       Date:  2021-09-21       Impact factor: 9.423

Review 4.  Glial-Neuronal Interactions in Pathogenesis and Treatment of Spinal Cord Injury.

Authors:  Nadezda Lukacova; Alexandra Kisucka; Katarina Kiss Bimbova; Maria Bacova; Maria Ileninova; Tomas Kuruc; Jan Galik
Journal:  Int J Mol Sci       Date:  2021-12-17       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.